Please login to the form below
ImClone
This page shows the latest ImClone news and features for those working in and with pharma, biotech and healthcare.
Lilly closes on first approval for sarcoma drug Lartruvo
Lilly acquired the antibody as part of its $6.5bn takeover of ImClone in 2008.
Latest news
-
BMS gives Erbitux rights to Lilly in the US
The companies' decision comes after a successful collaboration that lasted 14 years through Lilly's wholly-owned subsidiary ImClone. ... Our good work on Erbitux began with its development at ImClone and has continued with Bristol-Myers Squibb.
-
EU approval for Lilly's Cyramza in stomach cancer
takeover of the drug's developer ImClone in 2008.
-
Cyramza gets FDA green light in lung cancer
Lilly acquired Cyramza as part of its $6.5bn takeover of ImClone back in 2008.
-
Lilly closes in on another Cyramza indication
Necitumumab has been granted fast-track status by the FDA. Both ramucirumab and necitumumab were acquired by Lilly when it took over ImClone Systems in 2008 for $6.5bn.
-
Lilly’s Cyramza disappoints in liver cancer
Cyramza (ramucirumab) was acquired by Lilly via its purchase of ImClone Systems in 2008 and the drug has been tipped as one of its main prospects in oncology due in part
More from news
Approximately 0 fully matching, plus 37 partially matching documents found.
Latest appointments
-
Sue Mahony to retire as president of Lilly Oncology
Mahony led Lilly Oncology through the integration of ImClone and launched several brands including Verzenio.
-
VC firm expands team, appoints Genzyme and Lilly veterans
The firm, which focuses on building healthcare companies, has appointed former executives from Genzyme, Lilly, ImClone and Alnylam to help it translate scientific innovation into new companies. ... Also joining Third Rock as venture partners are Daniel
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- Want the most from your Pharmaceutical portfolio?
- Diversity and inclusion in clinical trials: keeping up momentum
- 10 Important Advisor Questions: Placement of Your Product in the Current/Future Treatment Algorithm
- Merck announces partnerships worth $1.3bn with BenevolentAI and Exscientia
- EC approves Menarini Group’s Orserdu for advanced or metastatic breast cancer
- Eli Lilly files US lawsuits over ‘unlawful’ sales of Mounjaro counterfeits
No results were found
PMHub
Six Degrees Medical Consulting
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
